Head And Neck Cancer Therapeutics Industry Poised for Rapid Expansion, Projected to Hit $2.8 Billion by 2029
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What Is the Outlook for the Head And Neck Cancer Therapeutics Market Heading Into 2029?
The market size for therapeutics in head and neck cancer has rapidly expanded in the past few years. This market is projected to increase from $1.71 billion in 2024 to $1.88 billion in 2025, rising at a compound annual growth rate (CAGR) of 10.3%. Factors such as tobacco and alcohol use, human papillomavirus (HPV) infections, environmental exposures, and advancements in treatment methodology contributed to the growth seen in the historical period.
The market size for therapeutics in head and neck cancer is projected to witness swift expansion in the forthcoming years. The estimation for its growth is $2.8 billion by 2029, with a compound annual growth rate (CAGR) of 10.4%. Factors contributing to this growth in the projected period include advancements in immunotherapy, precision medicine tactics, campaigns promoting awareness and early detection, and global aging population. Key trends for the forecast period encompass the growing importance of targeted therapies, the uptake of minimally invasive surgical methods, incorporation of palliative care, research on new biomarkers, and the adoption of care models focused on the patient.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12426&type=smp
Which Factors Are Pushing The Head And Neck Cancer Therapeutics Market Forward?
The growth of the head and neck cancer therapeutics market is likely to be fuelled by the escalating occurrence of head and neck cancer. This type of cancer is characterized by unregulated cell growth in the tissues of the head and neck region. As the number of cases increase, there is a heightened demand for superior diagnostic and therapeutic measures to address cellular mutations and abnormalities. For example, Cancer Research UK, an independent cancer research organization based in the UK, has forecasted that the incidence of head and neck cancer in the UK will surge by 3% between 2023 and 2025, while fatalities resulting from these cancers are anticipated to go up by 12% within the same period. Hence, the rising incidence of head and neck cancer is propelling the head and neck cancer therapeutics market.
Which Segment Held The Largest Share In The Head And Neck Cancer Therapeutics Market In 2025?
The head and neck cancer therapeutics market covered in this report is segmented –
1) By Type: Programmed Cell Death (PD) Inhibitors, Microtubule Inhibitors, Epidermal Growth Factor Receptor (EGFR) Inhibitors
2) By Route Of Administration: Injectable, Oral
3) By Distribution Channel: Retail And Specialty Pharmacies, Hospital Pharmacies, Online Pharmacies
4) By Application: Surgery, Radiation Therapy, Chemotherapy, Immunotherapy, Other Applications
Subsegments:
1) By Programmed Cell Death (PD) Inhibitors: PD-1 Inhibitors, PD-L1 Inhibitors
2) By Microtubule Inhibitors: Taxanes, Vinca Alkaloids
3) By Epidermal Growth Factor Receptor (EGFR) Inhibitors: Monoclonal Antibodies, Tyrosine Kinase Inhibitors
How Are Key Trends Driving Expansion In The Head And Neck Cancer Therapeutics Industry?
Key players in the market for head and neck cancer therapeutics are focusing their energies on developing new medicinal treatments for patients battling with head and neck cancer. The term drug treatment is applied to the employment of pharmaceutical compounds or medicines to treat, control or relieve diseases, conditions or symptoms in human beings. For example, Coherus BioSciences Inc., an American firm specializing in biopharmaceuticals, declared in October 2023 that the FDA had approved their new medication ‘Loqtorzi’. Also known as toripalimab-tpzi, the approval allowed for its use alongside cisplatin and gemcitabine as the primary course of treatment for adults suffering from metastatic or recurrent, locally advanced nasopharyngeal carcinoma. The trial resulted in less than 20% of patients experiencing adverse reactions, regardless of whether the treatment was used initially or administered as a standalone therapy.
Which Organizations Are Driving Progress In The Head And Neck Cancer Therapeutics Industry?
Major companies operating in the head and neck cancer therapeutics market include Pfizer Inc., F Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi Aventis LLC, Bristol-Myers-Squibb Company, AstraZeneca PLC, GlaxoSmithKline plc., Takeda Pharmaceutical Company Limited, Eli Lilly and Company, Amgen Inc., Boehringer Ingelheim International GmbH, Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Daiichi Sankyo Company Limited, Eisai Co. Ltd., Sun Pharmaceutical Industries Ltd., Incyte Corporation, Ono Pharmaceutical Co. Ltd., Kyowa Kirin Co. Ltd., Hikma Pharmaceuticals PLC, Clinigen Group plc., Ligand Pharmaceuticals, Acceleron Pharma Inc., Taiho Pharmaceutical Co. Ltd., Boston Biomedical Inc., AB Science SA.
Get The Full Report Here:
Which Region Is Expected To Experience The Highest Growth In The Head And Neck Cancer Therapeutics Industry?
North America was the largest region in the head and neck cancer therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the head and neck cancer therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=12426&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
